Another possible explanation may be that the with sorafenib patient group had higher percentages of high AFP (≥400 ng/mL) levels, although not reaching statistical significance, which have been shown to be an adverse prognostic factor for mortality in patients with advanced HCC [20], although not in our series of the 71 Vp4 patients. Here, AFP is linked to hepatocellular carcinoma.